IL145514A0 - Akt nucleic acids, polypeptides, and uses thereof - Google Patents

Akt nucleic acids, polypeptides, and uses thereof

Info

Publication number: IL145514A0
Authority: IL; Israel
Prior art keywords: polypeptides; nucleic acids; akt3; akt nucleic; relates
Prior art date: 1999-03-19

Application number

IL14551400A

Other languages

English (en)

Original Assignee

Aventis Pharm Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-19

Filing date

2000-03-14

Publication date

2002-06-30

2000-03-14 Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc

2002-06-30 Publication of IL145514A0 publication Critical patent/IL145514A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Immunology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Heart & Thoracic Surgery (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Enzymes And Modification Thereof (AREA)

IL14551400A 1999-03-19 2000-03-14 Akt nucleic acids, polypeptides, and uses thereof IL145514A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12510899P	1999-03-19	1999-03-19
PCT/US2000/006574 WO2000056866A2 (en)	1999-03-19	2000-03-14	Akt-3 nucleic acids, polypeptides, and uses thereof

Publications (1)

Publication Number	Publication Date
IL145514A0 true IL145514A0 (en)	2002-06-30

Family

ID=22418217

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
IL14551400A IL145514A0 (en)	1999-03-19	2000-03-14	Akt nucleic acids, polypeptides, and uses thereof
IL14198400A IL141984A0 (en)	1999-03-19	2000-03-14	Akt nucleic acids, polypeptides, and uses thereof
IL145514A IL145514A (en)	1999-03-19	2001-09-20	Akt nucleic acids, vectors, host cells, antibodies, recombinant viruses, methods and pharmaceutical compositions thereof
IL190270A IL190270A (en)	1999-03-19	2008-03-18	Use of 3AKT nucleic acids for the preparation of a drug for the treatment of cell death, treatment of myocardial infarction or injury due to blockage in the blood supply

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
IL14198400A IL141984A0 (en)	1999-03-19	2000-03-14	Akt nucleic acids, polypeptides, and uses thereof
IL145514A IL145514A (en)	1999-03-19	2001-09-20	Akt nucleic acids, vectors, host cells, antibodies, recombinant viruses, methods and pharmaceutical compositions thereof
IL190270A IL190270A (en)	1999-03-19	2008-03-18	Use of 3AKT nucleic acids for the preparation of a drug for the treatment of cell death, treatment of myocardial infarction or injury due to blockage in the blood supply

Country Status (18)

Country	Link
EP (1)	EP1144600B1 (xx)
JP (1)	JP4237945B2 (xx)
KR (1)	KR100700908B1 (xx)
AT (1)	ATE402995T1 (xx)
AU (1)	AU782448B2 (xx)
BR (1)	BR0009170A (xx)
CA (1)	CA2343074C (xx)
CY (1)	CY1108459T1 (xx)
DE (1)	DE60039677D1 (xx)
DK (1)	DK1144600T3 (xx)
ES (1)	ES2310515T3 (xx)
HK (1)	HK1041288B (xx)
IL (4)	IL145514A0 (xx)
NO (1)	NO20014537L (xx)
PT (1)	PT1144600E (xx)
SI (1)	SI1144600T1 (xx)
WO (1)	WO2000056866A2 (xx)
ZA (1)	ZA200108414B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6881555B2 (en)	1999-03-19	2005-04-19	Aventis Pharmaceuticals Inc.	AKT nucleic acids, polypeptides, and uses thereof
EP1178722A4 (en)	1999-04-16	2003-03-05	Univ Yale	ENOS MUTATIONS FOR GENTHERAPY AND THERAPEUTIC SCREENING
IL146730A0 (en) *	1999-06-11	2002-07-25	Aventis Pharm Prod Inc	Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
WO2003063905A1 (fr) *	2002-01-31	2003-08-07	Center For Advanced Science And Technology Incubation, Ltd.	Medicaments preventifs ou remedes pour maladies immunologiques
US10517883B2 (en)	2003-06-27	2019-12-31	Zuli Holdings Ltd.	Method of treating acute myocardial infarction
US20060051407A1 (en) *	2003-06-27	2006-03-09	Yoram Richter	Method of treating ischemia-reperfusion injury
JPWO2005009470A1 (ja) *	2003-07-28	2006-09-28	財団法人大阪産業振興機構	Ａｓｋ１阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法
EP2304439A4 (en)	2008-05-29	2012-07-04	Nuclea Biotechnologies Llc	ANTI-phospho-AKT ANTIBODY
TWI625121B (zh)	2009-07-13	2018-06-01	基利科學股份有限公司	調節細胞凋亡信號之激酶的抑制劑
JP5705314B2 (ja)	2010-07-02	2015-04-22	ギリアードサイエンシーズ，インコーポレイテッド	アポトーシスシグナル調節キナーゼ阻害剤
UY34573A (es)	2012-01-27	2013-06-28	Gilead Sciences Inc	Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en)	2013-03-14	2018-06-12	Biorest Ltd.	Liposome formulation and manufacture
KR20170049605A (ko)	2014-09-24	2017-05-10	길리애드 사이언시즈, 인코포레이티드	간 질환의 치료 방법
MX2017008417A (es)	2014-12-23	2017-09-28	Gilead Sciences Inc	Procedimientos para preparar inhibidores de cinasa 1 reguladora de señal de apoptosis (ask1).
MA41252A (fr)	2014-12-23	2017-10-31	Gilead Sciences Inc	Formes solides d'un inhibiteur d'ask 1
EP3934699A4 (en)	2019-03-04	2022-12-21	The Trustees of The University of Pennsylvania	NEUROPROTECTIVE GENE THERAPY TARGETING THE AKT PATHWAY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08109197A (ja) *	1994-10-07	1996-04-30	Sumitomo Electric Ind Ltd	白血病腫瘍拒絶抗原ペプチド
ES2227614T3 (es) *	1995-11-16	2005-04-01	Novartis Ag	Metodo para seleccionar compuestos que interaccionan con la proteina quinasa rac.
US5958773A (en) *	1998-12-17	1999-09-28	Isis Pharmaceuticals Inc.	Antisense modulation of AKT-1 expression
GB9828375D0 (en) *	1998-12-22	1999-02-17	Janssen Pharmaceutica Nv	Human akt-3
US6043090A (en) *	1999-03-23	2000-03-28	Isis Pharmaceuticals Inc.	Antisense inhibition of human Akt-2 expression
AU3774500A (en) *	1999-03-31	2000-10-16	Curagen Corporation	Nucleic acids including open reading frames encoding polypeptides; "orfx"
IL146730A0 (en) *	1999-06-11	2002-07-25	Aventis Pharm Prod Inc	Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

2000
- 2000-03-14 IL IL14551400A patent/IL145514A0/xx unknown
- 2000-03-14 AU AU38802/00A patent/AU782448B2/en not_active Ceased
- 2000-03-14 ES ES00917899T patent/ES2310515T3/es not_active Expired - Lifetime
- 2000-03-14 IL IL14198400A patent/IL141984A0/xx unknown
- 2000-03-14 AT AT00917899T patent/ATE402995T1/de active
- 2000-03-14 DK DK00917899T patent/DK1144600T3/da active
- 2000-03-14 JP JP2000606725A patent/JP4237945B2/ja not_active Expired - Fee Related
- 2000-03-14 DE DE60039677T patent/DE60039677D1/de not_active Expired - Lifetime
- 2000-03-14 KR KR1020017011960A patent/KR100700908B1/ko not_active Expired - Fee Related
- 2000-03-14 BR BR0009170-7A patent/BR0009170A/pt not_active Application Discontinuation
- 2000-03-14 HK HK02102803.1A patent/HK1041288B/en not_active IP Right Cessation
- 2000-03-14 WO PCT/US2000/006574 patent/WO2000056866A2/en active Search and Examination
- 2000-03-14 EP EP00917899A patent/EP1144600B1/en not_active Expired - Lifetime
- 2000-03-14 SI SI200031007T patent/SI1144600T1/sl unknown
- 2000-03-14 CA CA2343074A patent/CA2343074C/en not_active Expired - Fee Related
- 2000-03-14 PT PT00917899T patent/PT1144600E/pt unknown
2001
- 2001-09-18 NO NO20014537A patent/NO20014537L/no unknown
- 2001-09-20 IL IL145514A patent/IL145514A/en not_active IP Right Cessation
- 2001-10-12 ZA ZA200108414A patent/ZA200108414B/xx unknown
2008
- 2008-03-18 IL IL190270A patent/IL190270A/en not_active IP Right Cessation
- 2008-10-27 CY CY20081101217T patent/CY1108459T1/el unknown

Also Published As

Publication number	Publication date
AU782448B2 (en)	2005-07-28
ATE402995T1 (de)	2008-08-15
EP1144600A2 (en)	2001-10-17
NO20014537L (no)	2001-10-31
PT1144600E (pt)	2008-10-10
BR0009170A (pt)	2002-04-30
WO2000056866A2 (en)	2000-09-28
IL145514A (en)	2010-05-17
DK1144600T3 (da)	2008-11-24
CY1108459T1 (el)	2013-09-04
DE60039677D1 (de)	2008-09-11
IL141984A0 (en)	2002-03-10
JP2002539781A (ja)	2002-11-26
ES2310515T3 (es)	2009-01-16
EP1144600B1 (en)	2008-07-30
NO20014537D0 (no)	2001-09-18
SI1144600T1 (sl)	2008-12-31
KR20020011972A (ko)	2002-02-09
CA2343074C (en)	2010-09-21
WO2000056866A9 (en)	2002-08-29
AU3880200A (en)	2000-10-09
HK1041288B (en)	2008-11-07
WO2000056866A3 (en)	2001-02-15
IL190270A (en)	2012-12-31
CA2343074A1 (en)	2000-09-28
ZA200108414B (en)	2003-03-26
JP4237945B2 (ja)	2009-03-11
KR100700908B1 (ko)	2007-03-29
HK1041288A1 (en)	2002-07-05

Publication	Publication Date	Title
CY1108459T1 (el)	2013-09-04	Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
WO2003103589A3 (en)	2004-11-25	USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS
NZ502392A (en)	2002-12-20	Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals
WO2000055345A3 (en)	2001-05-31	Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
BR9811956B1 (pt)	2010-06-01	naftiridinonas e composição farmacêutica compreendendo as mesmas.
MX344216B (es)	2016-12-07	Productos geneticos expresados de forma diferencial en tumores y su uso.
EP1005540A4 (en)	2003-04-02	IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
AU2790292A (en)	1993-04-27	Viral recombinant vectors for expression in muscle cells
WO2001034641A8 (en)	2002-05-10	Antimicrobial activity of the first cationic cluster of human lactoferrin
GB0418388D0 (en)	2004-09-22	Cell therapy
MXPA04001720A (es)	2004-05-31	Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
IL174645A0 (en)	2006-08-20	MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
AU2002304249A1 (en)	2002-12-23	Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
NZ516237A (en)	2004-03-26	Meth1 and meth2 polynucleotides and polypeptides
EE200000102A (et)	2000-12-15	Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
UA84831C2 (ru)	2008-12-10	Производные фактора коагуляции vii
WO2001077338A3 (en)	2002-08-29	Human protein kinases and protein kinase-like enzymes
WO2002014369A3 (en)	2002-09-12	Human kininogen d5 domain polypeptides and their use
WO2022248651A3 (en)	2023-02-02	Inhibitory nucleic acids for factor h family proteins
ES2164011A1 (es)	2002-02-01	Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
AU2002246455A1 (en)	2002-10-15	Fusion proteins for specific treatment of cancer and auto-immune diseases
HUP0300813A2 (hu)	2003-10-28	Gének, fehérjék és alkalmazásuk
DE602005021159D1 (de)	2010-06-17	Bakteriophagen- und prophagen-proteine in der krebsgentherapie
DE60034874D1 (de)	2007-06-28	Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
WO1998050397A3 (de)	1999-02-11	Chimäre oligonucleotide und ihre verwendung